GHRP-2: The Complete 2026 Guide (Mechanism, Dosing, Cost)

GHRP-2 at a glance:

• Drug class: Growth hormone secretagogue
• Route: subcutaneous injection (peptides) or oral (small molecules)
• Typical frequency: once daily to once weekly depending on agent
• Half-life: varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)

If you're trying to figure out whether GHRP-2 is right for you — or for someone you care about — the right starting point is the basic biology. GHRP-2 is a growth hormone secretagogue. Increased GH and IGF-1 levels.

What is GHRP-2?

Growth hormone secretagogues stimulate endogenous GH release through either the GHRH receptor (GHRH analogs) or the GHS-R1a/ghrelin receptor (ghrelin mimetics).

There is no single FDA-licensed manufacturer of GHRP-2 for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. GHRP-2 is not currently approved by the FDA for general human use. Available evidence comes from ongoing clinical trials. We do not endorse self-administration of unapproved compounds.

The drug class growth hormone secretagogue works by targeting specific receptor pathways. Here's what to expect.

How GHRP-2 Works in the Body

Growth hormone secretagogues stimulate endogenous GH release through either the GHRH receptor (GHRH analogs) or the GHS-R1a/ghrelin receptor (ghrelin mimetics). The receptor target — compound-specific — drives the downstream effects users care about: increased gh and igf-1 levels.

The pharmacokinetics matter for daily use. GHRP-2 has a half-life of varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677), which determines how often it is dosed. The standard route of administration is subcutaneous injection (peptides) or oral (small molecules), and the typical schedule is once daily to once weekly depending on agent.

For more detail on the underlying biology, see our breakdown of how GHRP-2 works.

Who Uses GHRP-2?

GHRP-2 is most relevant for people whose situation maps to its approved indications: specific approved members include sermorelin (historically, pediatric GHD) and tesamorelin (HIV-lipodystrophy); most others are research-only.

People who should avoid GHRP-2 include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of GHRP-2 include:

• injection-site reactions
• fluid retention
• joint pain
• headache

Serious risks — uncommon but worth knowing — include:

• impaired glucose tolerance
• carpal tunnel syndrome
• theoretical IGF-1-mediated effects on tumor growth

We have a more detailed breakdown in our GHRP-2 side-effects guide.

GHRP-2 vs Alternatives

Recombinant human growth hormone remains the standard for diagnosed GH deficiency. If you are weighing GHRP-2 against another option, our comparison pages include GHRP-2 Side Effects in 2026: Real Reports, Real Solutions, Real GHRP-2 Results: What 6 and 12 Months Actually Look Like, GHRP-2 Cost in 2026: What You'll Actually Pay (Real Numbers).

Bottom Line

GHRP-2 delivers what its label says it delivers. The case for it (or against it) comes down to your specific situation, not abstract comparisons. Phase 2 and 3 data show meaningful benefit, with phase 3 confirmation pending in some cases. If you are considering GHRP-2, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• GHRP-2 Side Effects in 2026: Real Reports, Real Solutions
• Real GHRP-2 Results: What 6 and 12 Months Actually Look Like
• GHRP-2 Cost in 2026: What You'll Actually Pay (Real Numbers)
• GHRP-2 Protocols: A Research-Based Overview (Not a Recommendation)
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.